Legend Biotech Corporation American Depositary Shares - LEGN STOCK NEWS

The "Europe Cell and Gene Therapy Market - Focused Insights 2023-2028" report, added by ResearchAndMarkets, provides a comprehensive analysis of the European market valued at $2.17 billion in 2022 and projected to reach $15.15 billion by 2028, marking a 38.20% CAGR. Key highlights include Zolgensma's revenue of $1.37 billion in 2022, with potential growth to $5.00 billion by 2026. The report examines over 1,564 clinical trials in Europe and profiles leading companies like Novartis, Gilead Sciences, and Legend Biotech. It emphasizes the importance of government and academic financing, contributing to market growth.

Venatorx Pharmaceuticals announces a significant change in its Board of Directors. Tomas J. Heyman has been appointed as the Non-Executive Chairman, succeeding Dr. Michael Diem, who has stepped down after six years of service. Heyman brings over 37 years of biopharmaceutical experience, including corporate strategy and business development, having managed $1.5 billion in capital at Johnson & Johnson's venture capital group. The company is focused on addressing multi-drug resistant infections with its lead product, cefepime-taniborbactam, which it plans to submit for FDA approval in 2023.

Legend Biotech Corporation (NASDAQ: LEGN), based in Somerset, NJ, has announced its participation in two upcoming investor conferences. The first is the Cowen 43rd Annual Healthcare Conference in Boston, MA on March 7, 2023, at 9:50 AM ET, featuring CEO Ying Huang, Ph.D. The second event is the Barclays Global Healthcare Conference in Miami, FL on March 14, 2023, at 10:15 AM ET, also presented by Dr. Huang. Legend Biotech focuses on developing novel therapies for life-threatening diseases through advanced cell therapies.

Legend Biotech Corporation (NASDAQ: LEGN) announced on February 17, 2023 that it has regained compliance with Nasdaq Listing Rules 5250(c)(2). This follows a notice of noncompliance received on January 6, 2023, due to the company’s failure to file an interim balance sheet and income statement for the quarter ended June 30, 2022. After a planned restatement of audited financial statements, the necessary Form 6-K was filed on February 17, 2023, addressing the compliance issue. Legend Biotech focuses on developing advanced cell therapies to treat life-threatening diseases.

Legend Biotech Corporation (NASDAQ: LEGN) announced that its Phase 3 study CARTITUDE-4, evaluating CARVYKTI® for relapsed and lenalidomide-refractory multiple myeloma, successfully met its primary endpoint. The study showed a statistically significant improvement in progression-free survival (PFS) compared to standard therapy during the first pre-specified interim analysis. Following an independent data monitoring committee's recommendation, the study has been unblinded. This international trial is the first to compare CAR-T therapy to standard treatments in this patient group. Results will be presented at an upcoming medical meeting, potentially guiding future regulatory discussions.

Legend Biotech Corporation (NASDAQ: LEGN) received a notice from Nasdaq on January 6, 2023, indicating non-compliance with Listing Rules due to a failure to file the interim balance sheet and income statement for the quarter ended June 30, 2022. The deadline for compliance was December 31, 2022, which has not been met due to a planned restatement of prior financial statements. The company has 60 days from the notice to submit a compliance proposal, with a potential extension to June 29, 2023, if accepted.

Legend Biotech Corporation (NASDAQ: LEGN) has announced its participation in the 41st annual JP Morgan Healthcare Conference in San Francisco, CA. CEO Ying Huang, PhD, will present on Tuesday, January 10, 2023, at 2:15 PM Pacific Time. The company is focused on developing novel therapies for life-threatening diseases, leveraging advanced cell therapies, including CAR T-cell and NK cell-based immunotherapy. Legend Biotech, headquartered in Somerset, New Jersey, strives to discover cutting-edge therapeutics globally.

Legend Biotech Corporation (NASDAQ: LEGN) announced the acceptance of its New Drug Application (NDA) for ciltacabtagene autoleucel (cilta-cel) by China's NMPA. This application is based on the CARTIFAN-1 Phase 2 clinical study data, focusing on patients with relapsed or refractory multiple myeloma who have undergone multiple prior therapies. The study indicated significant efficacy and safety of cilta-cel, addressing a critical unmet medical need due to rising incidence rates of multiple myeloma in China. Cilta-cel is already approved in the U.S., Japan, and has conditional authorization in Europe.

Legend Biotech Corporation (NASDAQ: LEGN) has announced its participation in several upcoming investor conferences. The events include the BMO Biopharma Spotlight Series: Oncology Day on November 9, 2022, and the Cowen 6th Annual IO Next Summit on November 11, 2022, both featuring presentations by CEO Ying Huang, Ph.D. Further conferences will take place in Miami on November 14, London on November 17, and New York on November 29, culminating with the Evercore ISI 5th Annual HealthCONx Conference on November 30, 2022.